Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status.
Adjuvant chemotherapy
EGFR mutation
Pathological stage
Primary lung adenocarcinoma
Relapse-free survival
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
09 Sep 2022
09 Sep 2022
Historique:
received:
29
05
2022
accepted:
05
09
2022
entrez:
9
9
2022
pubmed:
10
9
2022
medline:
14
9
2022
Statut:
epublish
Résumé
Pathological stage IB-IIIA lung adenocarcinoma with an epidermal growth factor receptor (EGFR) mutation (Mt) has a high recurrence rate even after complete resection. However, there have been few reports on the risk factors for Mt recurrence. This study aimed to analyze the clinicopathological factors related to the relapse-free survival (RFS) of patients with pathological stage IB-IIIA primary lung adenocarcinoma with and without an EGFR mutation. Patients who underwent curative surgery for Mt (n = 208) harboring the EGFR exon 21 L858R point mutation or EGFR exon 19 deletion mutation and EGFR mutation wild-type lung adenocarcinoma (Wt, n = 358) between January 2010 and December 2020 were included. Patients who received adjuvant EGFR-tyrosine kinase inhibitors were excluded. The prognostic factors for RFS were analyzed using a multivariable Cox regression analysis. The 5-year RFS rates in the Mt and Wt groups were 43.5 and 52.3%, respectively (p = 0.907). Prognostic factors for RFS in the Mt group included smoking history (hazard ratio [HR], 1.49; p = 0.049), blood vessel invasion (HR, 1.84; p = 0.023), and lymph node metastasis (HR, 1.96; p = 0.005). However, adjuvant chemotherapy was not a prognostic factor (HR, 1.02; p = 0.906). In contrast, positron emission tomography (PET) max standardized uptake value (SUV) ≥ 6.0 (HR, 1.53; p = 0.042), lymphatic vessel invasion (HR, 1.54; p = 0.036), lymph node metastasis (HR, 1.79; p = 0.002), and adjuvant chemotherapy (HR, 0.60; p = 0.008) were prognostic factors for RFS in the Wt group. Prognostic factors for RFS in stage IB-IIIA primary lung adenocarcinoma differ by epidermal growth factor receptor mutation status. The impact of adjuvant chemotherapy on RFS also differed by EGFR mutation status.
Sections du résumé
BACKGROUND
BACKGROUND
Pathological stage IB-IIIA lung adenocarcinoma with an epidermal growth factor receptor (EGFR) mutation (Mt) has a high recurrence rate even after complete resection. However, there have been few reports on the risk factors for Mt recurrence. This study aimed to analyze the clinicopathological factors related to the relapse-free survival (RFS) of patients with pathological stage IB-IIIA primary lung adenocarcinoma with and without an EGFR mutation.
METHODS
METHODS
Patients who underwent curative surgery for Mt (n = 208) harboring the EGFR exon 21 L858R point mutation or EGFR exon 19 deletion mutation and EGFR mutation wild-type lung adenocarcinoma (Wt, n = 358) between January 2010 and December 2020 were included. Patients who received adjuvant EGFR-tyrosine kinase inhibitors were excluded. The prognostic factors for RFS were analyzed using a multivariable Cox regression analysis.
RESULTS
RESULTS
The 5-year RFS rates in the Mt and Wt groups were 43.5 and 52.3%, respectively (p = 0.907). Prognostic factors for RFS in the Mt group included smoking history (hazard ratio [HR], 1.49; p = 0.049), blood vessel invasion (HR, 1.84; p = 0.023), and lymph node metastasis (HR, 1.96; p = 0.005). However, adjuvant chemotherapy was not a prognostic factor (HR, 1.02; p = 0.906). In contrast, positron emission tomography (PET) max standardized uptake value (SUV) ≥ 6.0 (HR, 1.53; p = 0.042), lymphatic vessel invasion (HR, 1.54; p = 0.036), lymph node metastasis (HR, 1.79; p = 0.002), and adjuvant chemotherapy (HR, 0.60; p = 0.008) were prognostic factors for RFS in the Wt group.
CONCLUSIONS
CONCLUSIONS
Prognostic factors for RFS in stage IB-IIIA primary lung adenocarcinoma differ by epidermal growth factor receptor mutation status. The impact of adjuvant chemotherapy on RFS also differed by EGFR mutation status.
Identifiants
pubmed: 36085020
doi: 10.1186/s12885-022-10057-w
pii: 10.1186/s12885-022-10057-w
pmc: PMC9463865
doi:
Substances chimiques
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
966Informations de copyright
© 2022. The Author(s).
Références
J Thorac Oncol. 2013 Jan;8(1):52-61
pubmed: 23242438
Expert Rev Mol Diagn. 2017 Mar;17(3):209-215
pubmed: 28129709
J Mol Diagn. 2006 Sep;8(4):504-12
pubmed: 16931592
Lung Cancer. 2012 Aug;77(2):394-400
pubmed: 22542172
BMC Cancer. 2018 Oct 5;18(1):959
pubmed: 30290774
Gen Thorac Cardiovasc Surg. 2014 Feb;62(2):112-8
pubmed: 24186264
Cell. 2012 Sep 14;150(6):1107-20
pubmed: 22980975
Lung Cancer. 2020 Jul;145:111-118
pubmed: 32428800
Transl Lung Cancer Res. 2019 Dec;8(6):967-978
pubmed: 32010575
JAMA Netw Open. 2021 Nov 1;4(11):e2131892
pubmed: 34739062
Cancers (Basel). 2022 Mar 07;14(5):
pubmed: 35267664
Oncotarget. 2017 Oct 12;8(58):98384-98393
pubmed: 29228697
Oncologist. 2015 Mar;20(3):307-15
pubmed: 25657199
Cell. 2012 Sep 14;150(6):1121-34
pubmed: 22980976
Science. 2002 Jul 5;297(5578):63-4
pubmed: 12098689
J Thorac Dis. 2014 Oct;6(10):1420-8
pubmed: 25364519
J Thorac Oncol. 2012 Jul;7(7):1141-7
pubmed: 22617241
J Clin Pathol. 2013 May;66(5):381-5
pubmed: 23386666
EJC Suppl. 2013 Sep;11(2):137-49
pubmed: 26217123
J Thorac Cardiovasc Surg. 2022 Jan 26;:
pubmed: 35181001
Ther Adv Med Oncol. 2014 May;6(3):101-14
pubmed: 24790650
Lung Cancer. 2021 Dec;162:128-134
pubmed: 34775216
J Clin Oncol. 2021 Mar 1;39(7):713-722
pubmed: 33332190
Eur J Cardiothorac Surg. 2022 Mar 24;61(4):778-786
pubmed: 34686875
N Engl J Med. 2020 Jan 2;382(1):41-50
pubmed: 31751012
J Thorac Oncol. 2007 Jan;2(1):22-8
pubmed: 17410005
J Thorac Oncol. 2011 Jan;6(1):48-54
pubmed: 21079523
N Engl J Med. 2009 Sep 3;361(10):958-67
pubmed: 19692684
J Clin Oncol. 2022 Jan 20;40(3):231-241
pubmed: 34726958
Neoplasia. 2015 Aug;17(8):634-49
pubmed: 26408256
PLoS One. 2011;6(12):e28844
pubmed: 22194927
J Cell Physiol. 2011 Aug;226(8):2131-8
pubmed: 21520065
J Clin Oncol. 2015 Dec 1;33(34):4007-14
pubmed: 26324372
Lancet Oncol. 2014 Feb;15(2):213-22
pubmed: 24439929
Mol Diagn Ther. 2019 Oct;23(5):657-665
pubmed: 31347029
Am J Nucl Med Mol Imaging. 2018 Apr 25;8(2):100-109
pubmed: 29755843
J Thorac Cardiovasc Surg. 2018 Nov;156(5):2006-2015.e2
pubmed: 30104070
Lancet Oncol. 2018 Jan;19(1):139-148
pubmed: 29174310
J Clin Oncol. 2020 Jan 10;38(2):115-123
pubmed: 31682542
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
N Engl J Med. 2020 Oct 29;383(18):1711-1723
pubmed: 32955177
J Thorac Cardiovasc Surg. 2014 Jun;147(6):1820-6
pubmed: 24507979
J Thorac Oncol. 2015 Sep;10(9):1240-1242
pubmed: 26291007
Medicine (Baltimore). 2015 Oct;94(42):e1784
pubmed: 26496308